ClinicalTrials.gg
Enrolling by invitationNCT07395518Updated Aug 17, 2026

A Randomized Controlled Trial Comparing the Incidence of Surgical Site Infections in Cesarean Section With and Without Subcutaneous Drain Placement at Queen Savang Vadhana Memorial Hospital

An interventional study of Radivac drain in Surgical Site Infection (SSI), sponsored by Queen Savang Vadhana Memorial Hospital, Thailand. Enrolling by invitation at 1 site in Thailand. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Queen Savang Vadhana Memorial Hospital, Thailand · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jun 2025, registered Jan 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

To study and compare the incidence of surgical site infection after cesarean section in pregnant women with subcutaneous wound drainage and those without subcutaneous wound drainage at Queen Savang Vadhana Memorial Hospital, Sriracha. Chonburi Thailand

Read the detailed description

This study is a randomized controlled trial (RCT) designed to compare the incidence of surgical site infection after cesarean section between patients who receive subcutaneous wound drainage (Radivac drain) and those who do not. Postoperative wound follow-up will be conducted on postoperative days 3, 7, and 14.

Participants will be randomly assigned into two groups, with the control group consisting of pregnant women undergoing cesarean section at Queen Savang Vadhana Memorial Hospital, Sriracha. Data will be collected on surgical site infection, pain, postoperative complications, and length of hospital stay.

02

Conditions studied

  • Surgical Site Infection (SSI)

Keywords

  • Cesarean section wound infection
  • Subcutaneous incision drainage
  • Elective and Emergency Cesarean section wound infection.
03

In context

Surgical Wound Infection

747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.

This study's planned enrollment of 86 is below the median of 200 across 583 interventional studies indexed under Surgical Wound Infection.

Browse Surgical Wound Infection studies →

Lead sponsor

Queen Savang Vadhana Memorial Hospital, Thailand is the lead sponsor of 30 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Able to communicate in Thai
  • Undergoing cesarean section, both elective and emergency procedures
  • Subcutaneous fat thickness ≥ 4 cm, measured preoperatively using a standardized ultrasound technique
  • Able to return for postpartum follow-up at Somdech Phra Boromrajthevi Hospital, Sriracha
  • Willing to participate in the study and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Pregnant women with chronic conditions, such as systemic lupus erythematosus (SLE), infection, severe anemia ( \< 10.0 g/dL), or uncontrolled diabetes
  • Presence of skin disease or skin infection at the abdominal surgical site
  • Evidence of infection prior to cesarean section
  • Abnormal bleeding disorders requiring specialized treatment
  • History of allergy to, or complications from, the use of wound drainage systems
  • Refusal to participate in the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
86 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Pregnant women undergoing cesarean section with placement of a subcutaneous wound drain.

    Device: Radivac drain

  • No intervention
    Control group

    Pregnant women undergoing cesarean section without placement of a subcutaneous wound drain.

Interventions

  • DeviceRadivac drain

    In the intervention group, a subcutaneous wound drain is placed using a closed suction Redivac drain (10-14 French). The drain is inserted into the subcutaneous layer above the surgical incision through a skin exit site located 2-3 cm from the wound edge, avoiding visible vessels to reduce bleeding. A trocar is used to guide placement, ensuring the drain lies transversely beneath and covers the entire length of the incision. The drain is secured to the skin with silk sutures, connected to a Redivac suction system to apply negative pressure, and covered with a sterile dressing after skin closure to reduce the risk of contamination.

06

What researchers measure

Primary outcomes

  1. Primary outcome

    To compare the incidence of surgical site infection after cesarean section in pregnant women with and without subcutaneous wound drainage.

    Time frame: 14 days

Secondary outcomes

  1. Length of hospital stay

    Length of hospital stay

    Time frame: 14 days

07

Study locations

1 site
  • Queen Savang vadhana Memmorial Hospital
    Chon Buri, Changwat Chon Buri 20110, Thailand
08

References and documents

Individual participant data

Plan to share: Undecided — Data was save in form of microsoft excel spreadsheet and SPSS file

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in May 2026, 11 months.

Of 202 non-industry interventional studies with no phase under Surgical Wound Infection, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 47. This study's 11 months is below that.

Counting every sponsor, half of 209 studies reached it within 24 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2026
First posted
Feb 9, 2026
StartActual
Jun 1, 2025
Primary completionActual
May 1, 2026
CompletionEst.
Dec 29, 2026
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07395518
Lead sponsor
Queen Savang Vadhana Memorial Hospital, Thailand
Responsible party
Sponsor
First posted
Feb 9, 2026
Start date
Jun 1, 2025
Primary completion
May 1, 2026
Completion
Dec 29, 2026 (estimated)
Last update
Aug 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion